Current therapies for mycosis fungoides

[1]  Treatment of mycosis fungoides: results from a large international study , 2021 .

[2]  T. Miyagaki,et al.  Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy , 2021, Current Treatment Options in Oncology.

[3]  U. Hegde,et al.  Complete response of penile mycosis fungoides with systemic brentuximab therapy , 2020, Urology case reports.

[4]  J. Scarisbrick,et al.  Lack of Systemic Absorption of Topical Mechlorethamine Gel in Patients With Mycosis Fungoides Cutaneous T-Cell Lymphoma. , 2020, The Journal of investigative dermatology.

[5]  Jie Liu,et al.  Real-world data on the effectiveness and safety of interferon-alpha-2a intralesional injection for the treatment of focally recalcitrant mycosis fungoides , 2020, Annals of translational medicine.

[6]  A. Pileri,et al.  Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides) , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[7]  E. Guenova,et al.  Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020 , 2020, International Archives of Allergy and Immunology.

[8]  A. Stratigos,et al.  Monotherapy and combination therapy with acitretin for mycosis fungoides: results of a retrospective, multicentre study , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  A. Rook,et al.  Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy , 2020, Expert review of anticancer therapy.

[10]  C. Querfeld,et al.  Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study. , 2020, Journal of the American Academy of Dermatology.

[11]  P. Porcu,et al.  A prospective cohort study of Condensed low dose total skin electron beam therapy for mycosis fungoides: reduction of disease burden and improvement in quality of life. , 2020, Journal of the American Academy of Dermatology.

[12]  A. Combalia,et al.  RF - Brentuximab as Treatment for CD30+ Primary Cutaneous Lymphoma , 2019, Actas Dermo-Sifiliográficas (English Edition).

[13]  V. Venning,et al.  Management of cutaneous T‐cell lymphomas: Established and emergent therapies , 2019, The Australasian journal of dermatology.

[14]  J. Sun,et al.  Brentuximab vedotin: unexpectedly good response in CD30– mycosis fungoides , 2019, The British journal of dermatology.

[15]  A. Pileri,et al.  New therapies and old side‐effects in mycosis fungoides treatment: brentuximab vedotin‐induced alopecia , 2019, The British journal of dermatology.

[16]  T. Miyagaki,et al.  Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome , 2019, Front. Med..

[17]  E. Jaffe,et al.  The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. , 2019, Blood.

[18]  A. Benider,et al.  Radiation therapy in mycosis fungoid patient , 2019, The Pan African medical journal.

[19]  M. Hordinsky,et al.  Impressive response of CD30‐negative, treatment‐refractory mycosis fungoides to brentuximab vedotin , 2019, Dermatologic therapy.

[20]  P. Porcu,et al.  Allogeneic hematopoietic stem cell transplantation in advanced stage mycosis fungoides and Sézary syndrome: a concise review. , 2019, Chinese clinical oncology.

[21]  M. Duvic,et al.  Antibody-Based Therapies for Cutaneous T-Cell Lymphoma , 2018, American Journal of Clinical Dermatology.

[22]  Александр Григорьевич Румянцев,et al.  Т-клеточные лимфомы кожи: современные данные патогенеза, клиники и терапии , 2018 .

[23]  M. Beylot-Barry,et al.  Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study , 2018, The British journal of dermatology.

[24]  S. Bates,et al.  Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma , 2018, American Journal of Clinical Dermatology.

[25]  Esther J Kim,et al.  Mycosis fungoides occurring at the site of previous herpes zoster eruption , 2018, The Australasian journal of dermatology.

[26]  L. Cerroni.  Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment. , 2018, Seminars in cutaneous medicine and surgery.

[27]  Tyler Enos,et al.  Brentuximab vedotin in CD30+ primary cutaneous T‐cell lymphomas: a review and analysis of existing data , 2017, International journal of dermatology.

[28]  J. Scarisbrick.  Brentuximab vedotin is an effective therapy for CD30+ mycosis fungoides and cutaneous anaplastic large‐cell lymphoma: what is the cost? , 2017, The British journal of dermatology.

[29]  Ellen J. Kim,et al.  Topical Carmustine as Monotherapy or as Multimodality Therapy for Folliculotropic Mycosis Fungoides. , 2017, Acta dermato-venereologica.

[30]  M. Duvic,et al.  Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series , 2017, The Journal of dermatological treatment.

[31]  S. Whittaker,et al.  Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. , 2016, Clinical lymphoma, myeloma & leukemia.

[32]  S. Fuji,et al.  Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. , 2016, Stem cell investigation.

[33]  E. Olsen,et al.  Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium. , 2016, Journal of the American Academy of Dermatology.

[34]  Ellen J. Kim,et al.  The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma. , 2015, Dermatologic clinics.

[35]  A. Rook,et al.  The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma. , 2015, Dermatologic clinics.